SCHEMBL4002464

SCHEMBL4002464

CCCc1cccc(-c2cccc(-n3ncc(C(=O)O)c3C(F)(F)F)n2)c1OCc1ccc(-c2ccc(C(F)(F)F)cc2)cc1C

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 3/20 0.47
NFE2L2 Q16236 3/20 0.47
GUCY1A1 Q02108 14/20 0.46
GUCY1B1 Q02153 14/20 0.46
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ATM Q13315 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4005336 0.91 KEAP1 (0.48) KEAP1NFE2L2GUCY1A1GUCY1B1KDM4E
SCHEMBL3997084 0.89 KEAP1 (0.47) KEAP1NFE2L2GUCY1A1GUCY1B1KDM4E
SCHEMBL14952921 0.88 KEAP1 (0.50) KEAP1NFE2L2GUCY1A1GUCY1B1KDM4E
SCHEMBL1782292 0.85 KEAP1 (0.49) KEAP1NFE2L2GUCY1A1GUCY1B1KDM4E
SCHEMBL1782158 0.85 KEAP1 (0.49) KEAP1NFE2L2GUCY1A1GUCY1B1KDM4E
SCHEMBL3998296 0.84 KEAP1 (0.48) KEAP1NFE2L2GUCY1A1GUCY1B1KDM4E
SCHEMBL1780898 0.84 KEAP1 (0.48) KEAP1NFE2L2GUCY1A1GUCY1B1KDM4E
SCHEMBL3998938 0.84 KEAP1 (0.48) KEAP1NFE2L2GUCY1A1GUCY1B1KDM4E
SCHEMBL4000326 0.83 RAB9A (0.51) KEAP1NFE2L2GUCY1A1GUCY1B1KDM4E
SCHEMBL3997178 0.82 KEAP1 (0.51) KEAP1NFE2L2GUCY1A1GUCY1B1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594270-A2 The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) BIP Patents (DE) 2013-05-22 EP claimed
EP-2594270-A2 The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) BIP Patents (DE) 2013-05-22 EP disclosed
WO-2009071504-A1 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed